Clinical Data, Inc. (NASDAQ:CLDA) today announced the appointment of two new key members of the company’s senior management team: Carol Reed, M.D., as Senior Vice President and Chief Medical Officer, and John A. Schultz, as Senior Vice President, Business Development. Dr. Reed is joining Clinical Data following the completion of the company’s previously announced merger with Genaissance Pharmaceuticals, Inc., where Dr. Reed served as that company’s Vice President, Medical Affairs since 2003. In her new role with Clinical Data, Dr. Reed, 52, will be responsible for Clinical Data’s drug-specific partnership collaborations and clinical programs. Dr. Reed joined Genaissance from Bayer Pharmaceuticals, Inc., where she was an Associate Medical Director in Pulmonary Medical Research. Previously, she was the Associate Director, Section of Pulmonary and Critical Care Medicine at the Hospital of St. Raphael and directed its Medical Intensive Care Unit. Dr. Reed received a M.S. in Molecular Biology from the University of Illinois and a M.D. from the Rush Medical College in Chicago. In the newly created position of Senior Vice President, Business Development, Mr. Schultz will be responsible for developing and managing Clinical Data’s business opportunities in the pharmacogenomics and biomarker diagnostics markets. Mr. Schultz, 43, most recently was Vice President, Business Development of Pathway Diagnostics Corporation, where he was responsible for the development of biomarker diagnostics business opportunities and out-licensing activities. Prior to Pathway Diagnostics, Mr. Schultz headed the Life Sciences Business Development activities at the Office of Intellectual Property Administration at UCLA, and prior to that position was Director of Business Development at Specialty Laboratories where he spearheaded their licensing activities. Mr. Schultz also has extensive experience in the clinical diagnostics market, including serving as General Manager for the ImmunoSystems’ Division of BioChem Pharma (now Shire Pharmaceuticals), as well as positions at Sigma-Aldrich Corp., Isolab Inc. (now Perkin Elmer) and Mallinckrodt’s Forma Scientific Division (now Thermo Electron).Mr. Schultz holds a Bachelor of Science degree from Washington State University and a Master of Business Administration Degree from The Garvin School of International Management. Israel M. Stein, MD, President and CEO of Clinical Data commented. “We are delighted to add seasoned senior executives of Carol and John’s caliber to the CLDA team, as we expand our diagnostic business into major new opportunities in the pharmacogenomics market.”
